Orchid Pharma net down at Rs 54.5 crore

Total operating income stands at Rs 256.78 crore for three months ended June, 2013

Gireesh Babu Chennai
Last Updated : Aug 14 2013 | 7:17 PM IST
Orchid Chemicals and Pharmaceuticals Ltd (OCPL) has posted a net loss of Rs 54.50 crore for the quarter ended June 30, 2013, compared to the net loss of Rs 50.80 crore for the quarter in 2012.

The total operating income stood at Rs 256.78 crore for the three months ended June, 2013, as against Rs 357.23 crore for the same period of last year, a drop of 28%.

The company has also informed that it is expecting the transaction of sales of its Penicillin and Penem Active Pharmaceutical Ingredient (API) business and the API facility in Maharashtra to Hospira Healthcare India Private Limited, to be completed before September 30, 2013. The company has earlier informed BSE that the deal agreement has been extended to the end of June 30, 2013.

In its filing of quarterly results today, the company said, "The Company has entered into a Business Transfer Agreement (BTA) dated August 29, 2012 with Hospira Healthcare India Private Limited for the sale and transfer of Orchid’s Penicillin and Penem API business and the API facility located in Aurangabad (Maharashtra) together with an associated Process R&D infrastructure located in Chennai.  The transaction is expected to be completed before September 30, 2013."

It may be noted that the company earlier said that it has received all the no objection certificates (NOCs) from the lenders to complete its $200 million deal with the Indian subsidiary of US-based Hospira Inc.

However, the company later went into Corporate Debt Restructuring (CDR) and considering the transaction also part of the CDR discusions, the process would take a little more time, said Ch Ram, head - corporate communications & investor relations, OCPL.

The company expects that once the CDR process is completed there would be an ease in flow of working capital, which would help the company in returning to growth, he added.

The company has extended its financial year (FY 2012-13) by six months to September 30, 2013.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 14 2013 | 7:11 PM IST

Next Story